NCT01706679View on ClinicalTrials.gov

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

PHASE1CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

June 30, 2013

Conditions
Healthy
Interventions
DRUG

ATX-101 (10 mg/ml)

DRUG

ATX-101 (20 mg/ml)

DRUG

Moxifloxacin (400 mg)

DRUG

Placebo vehicle (PBS)

Trial Locations (1)

33027

Comprehensive Clinical Development, Miramar

Sponsors
All Listed Sponsors
lead

Kythera Biopharmaceuticals

INDUSTRY